Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Appropriate Antibiotic Use for Acute Otitis Media
Your Article Summary
See Latest ArticlesPepsin as a causal agent of inflammation during nonacidic reflux
Otolaryngology Head and Neck Surgery, 10/28/09
Samuels TL et al. – Exposure of hypopharyngeal cells to pepsin in a nonacidic environment induces the expression of several pro–inflammatory cytokines and receptors, including those known to be involved in inflammation of esophageal epithelium in response to reflux and which contribute to the pathophysiology of reflux esophagitis. These data indicate that refluxed pepsin may contribute to laryngeal inflammation associated with nonacidic gastric reflux, including that experienced by patients despite maximal acid suppression therapy.
Today in Head and Neck...keeping you current
Receive free subspecialty "5-minute updates" via email
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial
Journal of Clinical Oncology, 11/25/09
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
The Lancet Oncology - Online First, 11/12/09
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Annals of Oncology, 11/10/09
Article Search
Sponsor